x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243304
| Product Information | |
|---|---|
| CAS No. | 1623143-67-8 |
| Formula | C28H27FNNaO4 |
| Molecular Weight | 483.51 |
| SMILES | FC1=CC(C2=CC(OC)=NC=C2)=CC=C1[C@@H]3CCC(C=CC([C@H](C4CC4)[C@H](C)C(O[Na])=O)=C5)=C5O3 |
| Target | Free Fatty Acid Receptor |
| Product Description | AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC50 values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research. |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
